Tillmann Michels

Tillmann Michels has worked for a number of companies since 2008. Tillmann began their career as an intern at Janssen, Pharmaceutical Companies of Johnson and Johnson in 2008. In 2012, they became a PhD Student at the dkfz - German Cancer Research Center and also worked as an intern at UPMC. In 2015, they were Head of Immune Checkpoint Discovery at the Regensburg Center for Interventional Immunology (RCI). Since 2016, they have been working at iOmx Therapeutics AG, where they have held the roles of Associate Director Target Discovery, Team Leader Early Discovery/Biomarker, and Scientific Advisor.

Tillmann Michels earned a Bachelor of Science (BS) in Molecular Biotechnology from Heidelberg University in 2009, followed by a Master of Science (MS) in Molecular Biotechnology from the same institution in 2012. Tillmann then completed a Doctor of Philosophy - PhD in Biology from the DKFZ German Cancer Research Center in 2017, as well as a Doctor of Philosophy - PhD in Tumor Immunology from Heidelberg University the same year.